IN2014CN01970A - - Google Patents

Download PDF

Info

Publication number
IN2014CN01970A
IN2014CN01970A IN1970CHN2014A IN2014CN01970A IN 2014CN01970 A IN2014CN01970 A IN 2014CN01970A IN 1970CHN2014 A IN1970CHN2014 A IN 1970CHN2014A IN 2014CN01970 A IN2014CN01970 A IN 2014CN01970A
Authority
IN
India
Prior art keywords
biomarkers
event
years
risk
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Rosalynn Dianne Gill
Stephen Alaric Williams
Alex A E Stewart
Robert Mehler
Trudi Foreman
Britta Singer
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of IN2014CN01970A publication Critical patent/IN2014CN01970A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
IN1970CHN2014 2011-09-30 2012-09-28 IN2014CN01970A (2)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541828P 2011-09-30 2011-09-30
PCT/US2012/058060 WO2013049674A1 (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Publications (1)

Publication Number Publication Date
IN2014CN01970A true IN2014CN01970A (2) 2015-05-29

Family

ID=47993164

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1970CHN2014 IN2014CN01970A (2) 2011-09-30 2012-09-28

Country Status (16)

Country Link
US (3) US20130085079A1 (2)
EP (1) EP2761289B1 (2)
JP (3) JP6652781B2 (2)
KR (2) KR102248900B1 (2)
CN (4) CN103959060B (2)
AU (1) AU2013202112B9 (2)
BR (2) BR122019023720B1 (2)
CA (2) CA2847903C (2)
ES (1) ES2777002T3 (2)
IL (1) IL231387A (2)
IN (1) IN2014CN01970A (2)
MX (2) MX373248B (2)
RU (1) RU2651708C2 (2)
SG (3) SG10201607331WA (2)
WO (1) WO2013049674A1 (2)
ZA (1) ZA201401778B (2)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20130171649A1 (en) * 2010-06-07 2013-07-04 Manuel Mayr Methods and means for predicting or diagnosing diabetes or cardiovascular disorders based on micro rna
SG187045A1 (en) 2010-08-13 2013-02-28 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
AU2012225273B2 (en) 2011-03-10 2016-10-13 Somalogic, Inc. Aptamers for Clostridium difficile diagnostics
MX373248B (es) * 2011-09-30 2020-05-11 Somalogic Operating Co Inc Prediccion de riesgo de evento cardiovascular y usos del mismo.
WO2013113012A2 (en) 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
US20160289762A1 (en) 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
JP6198047B2 (ja) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 冠動脈疾患の検査キット
JP6506768B2 (ja) 2013-09-24 2019-04-24 ソマロジック・インコーポレーテッド 多重アプタマー標的の検出
WO2015140317A1 (en) * 2014-03-21 2015-09-24 Sanofi New markers for the assessment of the risk for development of a cardiovascular disorder
US20170102396A1 (en) * 2014-06-05 2017-04-13 Sanofi-Aventis Deutschland Gmbh New markers for the assessment of an increased risk for mortality
ES2792227T3 (es) * 2014-09-26 2020-11-10 Somalogic Inc Predicción de evento de riesgo cardiovascular y usos de la misma
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
CN108291330A (zh) * 2015-07-10 2018-07-17 西弗吉尼亚大学 卒中和卒中严重性的标志物
RU2602451C1 (ru) * 2015-08-28 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Способ диагностики генетической предрасположенности к развитию ишемического инсульта у больных с фибрилляцией предсердий
CN116008563B (zh) 2016-02-08 2025-12-19 私募蛋白质体操作有限公司 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
US20190071795A1 (en) * 2016-03-09 2019-03-07 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
AU2017245701A1 (en) * 2016-04-06 2018-08-23 Société des Produits Nestlé S.A. Biomarkers for predicting degree of weight loss
EP3440995B1 (en) * 2016-04-15 2021-06-16 Omron Corporation Biological information analysis device, system, and program
CN105907857A (zh) * 2016-04-29 2016-08-31 天津脉络生物科技有限公司 一种用于动脉血栓的分子标记物和试剂及其应用
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
ES2817087T3 (es) * 2016-08-04 2021-04-06 Hoffmann La Roche ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
BR112020011454A2 (pt) * 2017-12-13 2021-02-09 F. Hoffmann-La Roche Ag métodos para prever o risco de acidente vascular, para prever o risco de acidente vascular cerebral e para aprimorar a precisão da previsão e usos do (i) biomarcador ang-2 e/ou do biomarcador igfbp7
RU2685859C1 (ru) * 2018-07-04 2019-04-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития ишемического инсульта
CN109192250B (zh) * 2018-08-01 2021-12-07 华东理工大学 一种多相催化中克服表面物种快速迁移的加速模拟方法
KR20210044216A (ko) * 2018-08-10 2021-04-22 에프. 호프만-라 로슈 아게 심방세동-관련 뇌졸중 평가를 위한 ces-2 (카르복실에스테라제-2)
WO2020037244A1 (en) * 2018-08-17 2020-02-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Use of machine learning models for prediction of clinical outcomes
WO2020039001A1 (en) * 2018-08-22 2020-02-27 Roche Diagnostics Gmbh Circulating spon-1 (spondin-1) in the assessment of atrial fibrillation
EP3874275B1 (en) * 2018-10-31 2022-11-23 Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) Biomarkers of subclinical atherosclerosis
KR102125053B1 (ko) * 2018-12-14 2020-06-19 가톨릭대학교 산학협력단 심혈관계 질환의 검출용 조성물 및 이를 포함하는 키트
GB2612911B (en) 2019-02-14 2023-11-22 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
US11030743B2 (en) * 2019-05-16 2021-06-08 Tencent America LLC System and method for coronary calcium deposits detection and labeling
AU2020343243A1 (en) * 2019-09-03 2022-03-10 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
JP7510649B2 (ja) * 2019-11-06 2024-07-04 国立大学法人 香川大学 心不全マーカー
US20230170050A1 (en) * 2020-04-17 2023-06-01 Phenomic Ai System and method for profiling antibodies with high-content screening (hcs)
US10902955B1 (en) * 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
TW202201007A (zh) * 2020-05-19 2022-01-01 美商獵鷹生科有限責任公司 以灌注不足為特徵的病症的檢測和治療
FI130424B (en) * 2020-06-18 2023-08-23 Nightingale Health Oy Procedure for determining whether a subject has a disease or condition or whether the subject is at risk of developing a disease or condition
US20230393146A1 (en) * 2020-10-20 2023-12-07 Somalogic Operating Co., Inc. Cardiovascular Event Risk Prediction
RU2750716C1 (ru) * 2020-11-23 2021-07-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования сердечно-сосудистых осложнений у больных низкого или умеренного сердечно-сосудистого риска путем оценки их психологического статуса
US20240060998A1 (en) * 2021-02-01 2024-02-22 Medtronic, Inc. A method to identify lvad patients with elevated levels of blood activation using coupon tests
RU2757752C1 (ru) * 2021-04-26 2021-10-21 Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) Способ определения индивидуального профиля факторов суммарного сердечно-сосудистого риска у пациента трудоспособного возраста
US20250248660A1 (en) * 2021-08-26 2025-08-07 3P Healthcare Pty Ltd System and method for cardiovascular health assessment and risk management
US12412661B2 (en) 2021-11-25 2025-09-09 Samsung Electronics Co., Ltd. Electronic device and method of providing health guideline using the same
EP4230233A1 (en) * 2022-02-22 2023-08-23 mimiX Biotherapeutics Sàrl Method for producing tissue constructs
CA3248538A1 (en) * 2022-04-15 2023-10-19 Memorial Hospital For Cancer And Allied Diseases Multi-modal machine learning to determine risk stratification
CN115932276B (zh) * 2022-12-07 2025-09-02 首都医科大学附属北京安贞医院 一种检测生物标志物的产品在制备急性心肌梗死或其并发症的诊断的产品中用途
EP4698047A2 (en) * 2023-04-24 2026-02-25 Google LLC Deep learning-based photoplethysmography model for cardiovascular risk prediction
WO2026017134A1 (en) * 2024-07-19 2026-01-22 The University Of Hong Kong Methods and systems to determine early acute ischemic stroke (es) in acute ischemic stroke (ais) patients

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US20030144476A1 (en) * 2000-03-06 2003-07-31 Pankaj Agarwal Novel compounds
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
DK3072978T3 (en) * 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
JP2008523394A (ja) * 2004-12-10 2008-07-03 ユニヴァーシティー オブ メリーランド， バルティモア 炎症及び肥満症における血清アミロイドａタンパク質
CN2783324Y (zh) * 2005-04-28 2006-05-24 穆海东 心血管疾病诊断和预测多指标蛋白芯片检测试剂盒
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US20090226420A1 (en) * 2005-11-10 2009-09-10 Elizabeth Hauser Methods of Determining the Risk of Developing Coronary Artery Disease
CA2641189A1 (en) * 2006-01-31 2007-08-09 Mitsubishi Kagaku Iatron, Inc. Method for determination of condition of disseminated intravascular coagulation syndrome
WO2007103568A2 (en) * 2006-03-09 2007-09-13 Biosite, Inc. Methods and compositions for the diagnosis of diseases of the aorta
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
RU2376372C2 (ru) * 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
CA2693310C (en) * 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
GB0717637D0 (en) * 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
US20090186370A1 (en) * 2008-01-18 2009-07-23 Ogle Matthew F Diagnostic biomarkers for vascular aneurysm
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
CA2733556A1 (en) * 2008-08-11 2010-02-18 The Board Of Regents Of The University Of Texas System A micro-rna that promotes vascular integrity and uses thereof
JP5711131B2 (ja) * 2008-10-07 2015-04-30 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 最初の有害事象の予測のためのバイオマーカー
JP5678045B2 (ja) * 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
ES2623633T3 (es) * 2009-06-09 2017-07-11 Gendiag.Exe, S.L. Marcadores de riesgo para enfermedad cardiovascular
JP2012529914A (ja) * 2009-06-15 2012-11-29 カーディオ ディーエクス インコーポレイティッド 冠動脈疾患リスクの判定法
US9217747B2 (en) * 2009-10-29 2015-12-22 Health Diagnostic Laboratory, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
CN102762743A (zh) * 2009-12-09 2012-10-31 阿维埃尔公司 用于心血管疾病的诊断和分类的生物标记物检验
CA2808233C (en) * 2010-03-03 2017-07-11 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
MX373248B (es) * 2011-09-30 2020-05-11 Somalogic Operating Co Inc Prediccion de riesgo de evento cardiovascular y usos del mismo.
WO2013142114A1 (en) * 2012-03-19 2013-09-26 The Brigham And Women's Hosptial, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure

Also Published As

Publication number Publication date
EP2761289A1 (en) 2014-08-06
CA3074279A1 (en) 2013-04-04
HK1247666A1 (zh) 2018-09-28
EP2761289B1 (en) 2020-02-12
CA2847903C (en) 2020-10-27
ZA201401778B (en) 2018-08-25
US20150168423A1 (en) 2015-06-18
JP6546318B2 (ja) 2019-07-17
AU2013202112A1 (en) 2013-05-02
SG10201607331WA (en) 2016-11-29
BR112014007214A2 (pt) 2017-04-04
SG10201906900QA (en) 2019-09-27
RU2014110508A (ru) 2015-11-10
BR112014007214A8 (pt) 2022-07-26
AU2013202112B9 (en) 2015-10-22
JP2014528576A (ja) 2014-10-27
MX373248B (es) 2020-05-11
KR102111624B1 (ko) 2020-05-18
IL231387A0 (en) 2014-04-30
US20200166523A1 (en) 2020-05-28
ES2777002T3 (es) 2020-08-03
KR102248900B1 (ko) 2021-05-07
IL231387A (en) 2017-12-31
CN107422126A (zh) 2017-12-01
JP6917432B2 (ja) 2021-08-11
CN114518458A (zh) 2022-05-20
BR122019023720B1 (pt) 2023-01-24
KR20140084106A (ko) 2014-07-04
JP2018159713A (ja) 2018-10-11
KR20200055804A (ko) 2020-05-21
RU2651708C2 (ru) 2018-04-23
NZ622118A (en) 2016-01-29
CN103959060B (zh) 2017-05-17
MX2020004617A (es) 2020-08-06
MX2014003153A (es) 2014-04-30
BR122019023720A8 (pt) 2022-07-26
BR112014007214B1 (pt) 2022-08-16
EP2761289A4 (en) 2015-08-12
JP2020024216A (ja) 2020-02-13
AU2013202112B2 (en) 2015-09-24
CN103959060A (zh) 2014-07-30
BR122019023720A2 (2) 2017-04-04
WO2013049674A1 (en) 2013-04-04
CA2847903A1 (en) 2013-04-04
CN107422126B (zh) 2020-03-27
CN107102151A (zh) 2017-08-29
SG11201400904SA (en) 2014-04-28
US20130085079A1 (en) 2013-04-04
CA3074279C (en) 2021-10-19
JP6652781B2 (ja) 2020-02-26

Similar Documents

Publication Publication Date Title
IN2014CN01970A (2)
IN2014CN01787A (2)
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
EA030186B9 (ru) Способ проведения количественных анализов
MY170164A (en) Aptamer-based multiplexed assays
WO2014186761A3 (en) Methods for determining responsiveness to an anti-cd47 agent
WO2013052505A3 (en) Methods and devices for assessing risk to a putative offspring of developing a condition
WO2013075055A3 (en) Kits and methods for assessing appendicitis
EP3029153A3 (en) Mesothelioma biomarkers and uses thereof
HK1205764A1 (en) Tuberculosis biomarkers and uses thereof
WO2012019193A3 (en) Assay systems for genetic analysis
GB2515983A (en) Methods and compositions for providing a preeclampsia assessment
WO2013188686A3 (en) Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome
GB201207297D0 (en) Analytical methods and arrays for use in the same
MX2015001961A (es) Metodos y sistemas para ensayos.
IN2015DN01501A (2)
WO2011137388A3 (en) Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample
WO2012032345A3 (en) Biomarker signatures and uses thereof
MX371379B (es) Deteccion de la actividad de corte de una enzima.
EP3557259A3 (en) Methods and arrays for use in the same
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer
MX2019003931A (es) Metodo y sistema de analisis para analizar una muestra.
GB201206323D0 (en) Methods and arrays for use in the same
WO2014160237A3 (en) Methods of prognosing preeclampsia
EP4328324A3 (en) Methods of diagnosing epilepsy